Urgent.News

What's breaking now, across thousands of outlets.

More in Health & Medicine

Samsung Bioepis Initiates Phase 1 Clinical Trial for SB35, A Biosimilar Candidate Referencing Taltz (Ixekizumab)

Samsung Bioepis Co., Ltd. announced on Aug. 28 the initiation of Phase 1 clinical trial for SB35, a biosimilar candidate referencing Taltz (ixekizumab).The Phase 1 clinical trial for SB35 is a…

  • Samsung Bioepis begins Phase 1 trial for SB35 biosimilar on August 28
  • Study compares pharmacokinetics, safety, tolerability, immunogenicity of SB35 vs Taltz
  • Primary outcomes measured: AUCinf, Cmax, AUClast from Day 1 to Day 85

More from Friday 28 August →